Skip Navigation

European Heart Journal 2004 25(13):1091-1092; doi:10.1016/j.ehj.2004.05.001
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dobrev, D.
Right arrow Articles by Ravens, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dobrev, D.
Right arrow Articles by Ravens, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Muscarinic subtype-2 receptor autoantibodies: actors or bystanders in human atrial fibrillation?

Dobromir Dobrev*, Torsten Christ and Ursula Ravens

Department of Pharmacology and Toxicology, Dresden University of Technology, Dresden, Germany

* Correspondence to: Dobromir Dobrev, Department of Pharmacology and Toxicology, Dresden University of Technology, Fetscher Str 74, 01307 Dresden, Germany. Tel.: +49-351-458-6279; fax: +49-351-458-6315
E-mail address: dobrev@rcs.urz.tu-dresden.de

The first 10% of the full text of this article appears below.

This editorial refers to "Autoantibodies against M2 muscarinic acetylcholine receptors: new upstream targets in atrial fibrillation in patients with dilated cardiomyopathy"1 by A. Baba et al. on page 1108

Atrial fibrillation (AF) is currently the most common cardiac arrhythmia in the clinical setting. It is associated with a shortening of action potential duration (APD) and effective refractory period (ERP) and a loss of physiological rate-dependent adaptation that can be explained by concomitant alterations in ion channel activity.1 These electrophysiological changes (electrical remodelling) promote the induction and the persistence of the arrhythmia. In addition, changes . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Autoantibodies against M2-muscarinic acetylcholine receptors: new upstream targets in atrial fibrillation in patients with dilated cardiomyopathy
Akiyasu Baba, Tsutomu Yoshikawa, Yukiko Fukuda, Takashi Sugiyama, Megumi Shimada, Makoto Akaishi, Kanji Tsuchimoto, Satoshi Ogawa, and Michael Fu
EHJ 2004 25: 1108-1115. [Abstract] [FREE Full Text]